EssilorLuxottica

New Peer-Reviewed Study on Essilor Stellest 2.0 spectacle lenses with H.A.L.T.* MAX Technology Published in *Translational Vision Science & Technology*

Paris, France (13 November 2025) – EssilorLuxottica announces the publication of a new peer-reviewed research article in the medical journal *Translational Vision Science & Technology (TVST),* presenting data from a clinical study evaluating spectacle lenses with Highly Aspherical Lenslet Target (H.A.L.T.*) MAX technology.

The study provides clinical evidence demonstrating that Essilor Stellest 2.0 spectacle lenses with H.A.L.T.* MAX technology offer significantly higher efficacy in slowing axial elongation compared to Essilor Stellest lenses with H.A.L.T.* technology.†[1] The design of the Essilor Stellest lens is based on the hypothesis that a volume of signal is more effective at slowing myopia progression than a surface of signal[2,3]. In Essilor Stellest 2.0 lenses with H.A.L.T.* MAX technology, the power and asphericity of the lenslets were increased, so the volume of non-focused light is further from the retina and spread over a wider area compared to Essilor Stellest lenses. This design creates twice the depth of volume of non-focused light, generating a stronger optical signal, that helps slow axial elongation even further — delivering twice the power, ‡ higher efficacy in managing myopia progression.†[1]

"*These findings strengthen the clinical rationale that increasing lenslet power and asphericity can further slow axial elongation in children*," said Björn Drobe, Director, Applied Myopia Research, R&D, EssilorLuxottica. "*This evidence continues to guide our innovation efforts to develop solutions that combine clinical effectiveness with strong scientific validation*."

Conducted in Singapore, this one-year randomized contralateral crossover clinical trial involved 50 myopic children aged 6–10 years. Each participant wore spectacle lenses with H.A.L.T.* MAX technology in one eye and spectacle lenses with the original H.A.L.T.* technology design in the other for six months, then switched combinations for another six months. The primary outcome was axial length change, a key indicator of myopia progression.

A clear dose-response relationship was observed between lenslet power and asphericity and the efficacy in slowing axial elongation, reinforcing the underlying mechanism of action of H.A.L.T. * MAX technology. The study also demonstrates the ethical and effective use of contralateral crossover designs to reliably compare similar lens designs and support the enhanced clinical performance of spectacle lenses with H.A.L.T.* MAX technology over H.A.L.T*. technology.

The clinical trial results of Essilor Stellest 2.0 lenses were first presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City, marking their initial scientific disclosure.

Essilor Stellest 2.0 lenses are the company's most efficacious spectacle lens to date for slowing myopic eye growth. §[1] They are currently available in China with broader market rollouts planned for 2026 and beyond.

Building on the success of the Essilor Stellest lenses, which are already worn by millions of children worldwide and supported by clinical evidence, this advancement reinforces EssilorLuxottica's decades-long leadership and commitment to science-driven innovation and improved patient outcomes, especially for children with myopia. Through sustained investment in research and collaboration with the global eye care community, we continue to develop evidence-based solutions that set new standards in myopia management.

To read the full article in *Translational Vision Science & Technology journal,* **click here.**

Notes

* H.A.L.T., Highly Aspherical Lenslet Target

† Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children.

‡ Twice the power refers to two (or more) times the depth of volume of non-focused light (by design) compared to that of Essilor® Stellest® lenses—and is not associated with a doubling of lens power, lenslet power, or efficacy.

§ Compared to products within the Essilor® portfolio

1. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. *Transl Vis Sci Technol.* 2025;14(11):9. doi:10.1167/tvst.14.11.9.

2. Woods J, et al. Inhibition of Defocus-Induced Myopia in Chickens. *Invest Ophthalmol Vis Sci* 2013; 54: 2662–2668.

3. Irving EL, et al. Myopia progression control lens reverses induced myopia in chicks. *Ophthalmic Physiol Opt* 2017; 37: 576–584.

Contacts

Olga Prenat
Head of Medical & Professional Affairs
prenato@essilor.fr

Marco Catalani
Head of Corporate Communications
media@essilorluxottica.com

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. Its Mission is to help people around the world to see more and be more by addressing their evolving vision needs, personal style aspirations and desire to feel more connected to the world around them. EssilorLuxottica is home to the most innovative lens technologies, including Varilux, Stellest and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo. Backed by robust R&D investments, distinctive capabilities and a top-quality asset portfolio, the Company drives innovation across categories, from cutting-edge medical instruments and solutions for eye health to category-defining smart glasses, all of which push the boundaries of the industry and reimagine the eyes as a gateway to new possibilities. With over 200,000 employees across 150 countries, 600 operations facilities, serving 300,000 eye care professionals and operating 18,000 stores, the Group generated consolidated revenue of Euro 26.5 billion in 2024. Its OneSight EssilorLuxottica Foundation has given access to sustainable vision care to nearly 1 billion people in underserved communities. EssilorLuxottica trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP. www.essilorluxottica.com.